Scientists Uncover How Vaccine Adjuvants Separate Protection from Reactogenicity

Description

Published Article

"IL-1 delineates squalene-based adjuvant efficacy and reactogenicity in a cell-type-specific manner"

npj Vaccines Online 30 March 2026 doi:10.1038/s41541-026-01420-0

Yuya Yoshioka^1,2†, Anri Nishinaka-Yoshioka^1,2†, Kouji Kobiyama^2,3, Tomoya Hayashi², Yujiro Kidani¹, Yosuke Yanagida⁴, Junpei Kasahara⁴, Kenichiro Tsujii¹, Yoshiji Asaoka⁵, Norikazu Kuroda⁶, Akira Kugimiya⁶, Hiroaki Osawa¹, Akimasa Yoshimura¹, Motoyasu Onishi⁷, Takayuki Nakagawa¹, Satoru Ishida¹, Shinya Omoto¹, Morio Nagira¹, Cevayir Coban^8,9,10,11, and Ken J. Ishii^2,9,10,11*

1. Vaccine R&D Laboratory, Shionogi & Co., Ltd., Osaka, Japan

2. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo, Tokyo, Japan

3. Division of Rheumatology, Department of Medicine, University of California San Diego, La Jolla, CA 92093-0809, United States

4. Vaccine Manufacturing Technology Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan

5. Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd., Osaka, Japan

6. Laboratory for Medicinal Chemistry Research, Shionogi & Co., Ltd., Osaka, Japan

7. Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Osaka, Japan

8. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo, Tokyo, Japan

9. International Vaccine Design Center, The Institute of Medical Science (IMSUT), The University of Tokyo, Tokyo, Japan

10. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Tokyo, Japan

11. World Premier International Research Center (WPI) Immunology Frontier Research Center (IFReC), Osaka University, Osaka, Japan

^† These authors contributed equally: Yuya Yoshioka and Anri Nishinaka-Yoshioka

npj Vaccines